New reports have suggested that combination of anti-OX40/anti-CTLA-4 mAb greatly promoted survival rate in defectively immunogenic TRAMP-C1 murine prostate tumor cells and strong effector responses of CD4 and CD8 cells required to induce tumor regression (Redmond et al., 2014[77]). The gene discussed is TNFRSF4; the disease is neoplasm.